medigraphic.com
ISSN 0016-3813 (Print)

2019, Number 2

<< Back Next >>

Gac Med Mex 2019; 155 (2)

Síntesis y uso de histidinato de cobre en niños con enfermedad de Menkes en México

Flores-Pulido AA, Jiménez-Pérez N, García-Chong R

Language: Spanish
References: 13
Page: 191-195
PDF size: 242.86 Kb.


ABSTRACT

Menkes disease is a neurodegenerative and lethal pathology caused by gene mutations of the copper-transporting ATP-7A enzyme; it manifests itself by neurological symptoms and connective tissue changes of varying severity. Timely subcutaneous use of copper histidinate (Cu-His) is determinant for quality of life. We report the first experiences in Mexico on Cu-His synthesis and its safe use in 3 cases where hypocupremia and hypoceruloplasminemia were corroborated. With advice of the Hospital for Sick Children of Toronto Canada, we prepared a 500 µg/mL solution. In all three cases were 250 µg of Cu-His applied without relevant undesirable effects for 30 days. Serum copper (Cu, expressed in µg/L) and ceruloplasmin (Cp, in mg/dL) were determined: case 1, Cu days 0 and 30, 8 and 504 µg/L; Cp days 0 and 30, 4 and 10.75 mg/dL; case 2, Cu days 0 and 30, ‹50 and 502 µg/L; Cp days 0 and 30, 2 and 15 mg/dL; case 3, Cu days 0 and 30, 3 and 84.2 µg/L; Cp days 0 and 30, 4 and 10.7 mg/dL. In Mexico, it is possible to safely synthesize Cu-His and treat MD, which must be intentionally sought.


REFERENCES

  1. Carbajal-Rodríguez L, Belmont-Martínez L, González-Del Ángel A, Delgado- Falcón J, Durán-C, Rodríguez-Herrera R, et al. Síndrome de Menkes. Bol Med Hosp Infan Mex. 2002;59 365-371.

  2. Christodoulou J, Danks D, Sarkar B, Baerlocher K, Casey R, Horn N, et al. Early treatment of Menkes disease with parenteral cooper-histidine: long term follow-up of four treated patients. Am J Med Genet. 1998;76:154-164.

  3. Deschamps P, Kulkarni P, Gautam-Basak M, Sarkar B. The saga of copper (II)-L histidine. Coord Chem Rev. 2005;249:895-909.

  4. Ojha R, Prasad AN. Menkes disease: what a multidisciplinary approach can do. J Multidiscip Healthc. 2016;9:371-385.

  5. Garnica A, Chan WY, Rennert O. Copper-histidine treatment of Menkes disease. J Pediatr. 1994;125:336-338.

  6. León-García, Dávila-Gutiérrez. Estado actual de la enfermedad de Menkes en México. Salud Publica Mex. 2012;54:103-104.

  7. Menkes JH, Alter M, Steigleder GK, Weakley DR, Sung JH. A sex-linked recessive disorder with retardation of growth, peculiar hair, and focal cerebral and cerebellar degeneration. Pediatrics. 1962;29:761-779.

  8. Vía de administración subcutánea en lactantes e infantes. Disponible en: https://image.slidesharecdn.com/1-tecnicasdeaplicacion-1302011 20246-phpapp01/95/1tcnicas-de-aplicacin-vacunas-13-638.jpg?- cb=1359720489

  9. Sarkar B, Lingertat-Walsh K, Clarke JTR. Cooper histidine therapy for Menkes disease. J Pediatr. 1993;123:828-830.

  10. Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010;18:511‑518.

  11. Tümer Z, Chirstodoulou J, Clarke JTR, Sarkar B, Horn N. Early cooper histidine treatment for Menkes disease. Nat Genet. 1996;12:11-13.

  12. Kaler SG, Holmes CS, Goldstein DS, Tang J, Gosdwin S, Donsante A, et al. Neonatal diagnosis and treatment of Menkes disease. N Eng J Med. 2008;358 605-614.

  13. Sheela SR, Latha M, Liu P, Lem K, Kaler SG. Copper-replacement treatment for symptomatic Menkes disease: ethical considerations. Clin Genet. 2005;68:278-283.




2020     |     www.medigraphic.com